Cholangioscopy Shows Strong Accuracy for Detecting Bile Duct Cancer

For patients facing the terrifying possibility of bile duct cancer, the diagnostic journey is often exhausting and inconclusive. Scans can reveal a blockage, but they cannot tell doctors whether it is caused by a tumor, scarring, or inflammation. Now, a large international study has delivered some of the most robust real-world evidence yet that a minimally invasive camera-guided technique can peer directly inside the bile ducts and distinguish cancer from benign disease with impressive reliability. The findings, published in CVIR Oncology, could reshape how specialists work up some of the most diagnostically elusive lesions in the digestive system.

The research, led by Belarmino Gonçalves of the Portuguese Oncology Institute of Porto and Thiago Franchi Nunes of Interventix in Campo Grande, Brazil, brought together ten tertiary referral centers across South America and Europe. Between January 2018 and July 2025, the investigators analyzed 68 diagnostic percutaneous transhepatic cholangioscopy, or PTCS, procedures performed in patients whose cross-sectional imaging and prior endoscopic evaluation had been nondiagnostic, or whose anatomy made standard endoscopic access impossible. Crucially, cases performed primarily to treat gallstones were excluded, isolating a cohort in which the sole purpose of the camera voyage into the ducts was to determine whether cancer was present.

The technique itself is a remarkable feat of interventional radiology. Using ultrasound and fluoroscopic guidance, physicians thread a needle through the liver into the bile ducts and establish a percutaneous tract, typically secured with a 10 to 12 French introducer sheath. Through that sheath, flexible cholangioscopes, single-operator platforms, or single-use ultra-slim endoscopes measuring roughly 2.8 to 3.5 millimeters in outer diameter are advanced directly into the biliary tree. Saline irrigation clears the field, allowing the operator to inspect the duct lining in real time — something computed tomography and magnetic resonance cholangiopancreatography fundamentally cannot do, since they offer only indirect views of the biliary mucosa. Some centers perform the cholangioscopic inspection in the same session when tract and sheath conditions permit; others prefer a staged approach roughly 48 to 72 hours later to allow decompression and reduce infection risk in patients with cholangitis or complex anatomy.

During each procedure, operators recorded two kinds of optical judgments before any tissue results were known. The first was a global impression — a binary real-time call of benign versus malignant that integrated everything seen during the examination. The second was a checklist of five predefined visual criteria: tumor vessels appearing as tortuous neovessels, hypervascular mucosa, nodular or polypoid masses, papillary projections, and infiltrative lesions marked by irregular mucosa and loss of normal duct architecture. When recorded images or videos were available, blinded investigators independently reviewed the material against the checklist, with disagreements resolved by consensus, adding a layer of methodological rigor to what has historically been a subjective art.

The results against the gold standard of histopathology were striking. Malignancy was ultimately confirmed in 57 of the 68 procedures, reflecting the referral-enriched, high-risk nature of the population. Against that benchmark, the operator’s global impression achieved 84.2 percent sensitivity, 90.9 percent specificity, and 85.3 percent accuracy. Most notable was the positive predictive value of 98.0 percent: when an experienced operator called a lesion malignant on direct visualization, that call was almost always right. The negative predictive value of 52.6 percent, by contrast, shows that a benign-appearing duct cannot safely rule out cancer — tissue sampling remains essential. The authors caution that these predictive values must be interpreted in light of the unusually high cancer prevalence in this cohort.

Among the individual visual criteria, two emerged as the most trustworthy warning signs. An infiltrative appearance showed 90.9 percent specificity and was strongly associated with malignant histopathology, carrying an odds ratio of 13.75 and a positive predictive value of 97.1 percent. Tumor vessels were also significantly linked to cancer, with an odds ratio of 4.57. Hypervascular mucosa, by comparison, offered little discriminatory power. The researchers then explored combined decision rules: using the permissive rule of tumor vessels or infiltrative appearance raised sensitivity to 84.2 percent at moderate specificity, while the restrictive rule requiring both features achieved 100 percent specificity — a powerful rule-in finding when tissue is scarce — albeit with sensitivity dropping to 36.8 percent. These PTCS-specific heuristics remain hypothesis-generating and await prospective validation.

Safety data were equally informative. Adverse events occurred in 10 of 68 procedures, or 14.7 percent, graded using the modified CIRSE classification system. Two events were grade I, five were grade II, and three were grade IV — the latter all infectious complications requiring intensive care-level support such as vasopressors or ventilation, rather than mechanical injury from the instruments themselves. The predominance of low-grade complications underscores the importance of standardized antibiotic prophylaxis, careful biliary decompression, controlled irrigation strategies, and structured post-procedure monitoring for anyone undergoing antegrade cholangioscopy.

The study’s context matters. In patients with surgically altered anatomy — bilioenteric anastomoses or Roux-en-Y reconstructions accounted for nearly a third of the cohort — conventional endoscopic retrograde cholangiopancreatography is often impossible or has already failed. Traditional blind or fluoroscopy-guided biopsies perform poorly for infiltrative, flat, or submucosal tumors, frequently returning nondiagnostic or discordant samples. Prior meta-analyses have shown that cholangioscopy-guided targeted biopsy outperforms fluoroscopy-guided sampling for indeterminate strictures, and consensus guidelines now frame cholangioscopy as a problem-solving tool. What has been missing, the authors argue, is multicenter real-world evidence about how the percutaneous, antegrade version of the technique performs across diverse devices, operators, and health systems — a gap this Brazil-and-Europe network directly addresses.

The investigators are candid about the limitations. The retrospective design limits control of confounding and standardization, and partial verification bias is possible. The high prevalence of malignancy limits generalizability to lower-risk populations, and procedural heterogeneity — different scopes, sheath sizes, sedation protocols, and timing — reflects the reality of a varied referral network but complicates interpretation. Confidence intervals around some analyses were wide, and inter-observer reproducibility was not formally assessed. Still, the single-session design, which avoided within-patient clustering, and the combination of operator impression with structured criteria strengthen the findings considerably.

Looking ahead, the authors call for prospective validation of PTCS-specific optical reporting frameworks, standardized documentation of procedural variables such as tract maturation and irrigation strategy, and quantification of how cholangioscopic findings actually change patient management. Emerging technologies, including standardized image annotation and artificial intelligence-assisted pattern recognition, could sharpen interobserver agreement and refine the visual criteria tailored to percutaneous referral populations. For now, the message for patients with mysterious bile duct blockages is encouraging: a camera threaded through the liver, guided by a trained eye and a disciplined checklist, can bring clarity where scans and standard endoscopy leave only doubt — with a safety profile that is, in most cases, reassuringly benign.

Subject of Research: Diagnostic performance and safety of percutaneous transhepatic cholangioscopy for complex, indeterminate biliary lesions

Article Title: Percutaneous transhepatic cholangioscopy for complex biliary lesions: multicenter real-world diagnostic performance and safety study

Article References: Percutaneous transhepatic cholangioscopy for complex biliary lesions: multicenter real-world diagnostic performance and safety study. (n.d.). https://doi.org/10.1007/s44343-026-00045-3

Image Credits: AI Generated

DOI: 10.1007/s44343-026-00045-3

Keywords: percutaneous transhepatic cholangioscopy, biliary strictures, cholangiocarcinoma, indeterminate biliary lesions, targeted biopsy, interventional radiology, diagnostic accuracy, adverse events, multicenter study, bile duct cancer, Percutaneous, transhepatic